An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
- Status
- COMPLETED
- Phase
- PHASE1
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
- Status
- COMPLETED
- Phase
- PHASE2
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
TG4010 and Nivolumab in Patients With Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Nivolumab Plus Radiotherapy in Advanced Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1
- Status
- COMPLETED
- Phase
- PHASE1
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
- Status
- TERMINATED
- Phase
- PHASE3
Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2